A new, simple web-based calculator that could better predict the long term risk of breast cancer returning in other areas of the body has today been published online by researchers at The Royal Marsden NHS Foundation Trust and Queen Mary University of London.
The prognostic tool - CTS5 (Clinical Treatment Score post-5-years) - published recently in the Journal of Clinical Oncology, could be used to decide which patients are at high enough risk of their cancer returning after receiving the standard five years of endocrine (hormone) therapy, and so could benefit from continuation of treatment. It could also predict which patients are at low risk of recurrence, and so can avoid any further therapy along with the potential adverse side effects.
Over the last three decades, there has been a major increase in the rate of invasive breast cancer in Western countries. Approximately 85 per cent of patients are now diagnosed as oestrogen receptor (ER) positive, which means that the cancer grows in response to the hormone oestrogen. Almost all of these patients are prescribed five years of hormone therapy after having standard treatment (surgery, chemotherapy, and/or radiation therapy), to lower the risk of the cancer returning.
However, hormone therapy can have significant side effects for some patients, including weakness of bone tissue, and exacerbation of menopausal symptoms. Oncologists along with patients have to decide after five years of hormone treatment whether extending this type of therapy is worthwhile and appropriate.
Professor Mitch Dowsett, Head of The Royal Marsden Ralph Lauren Centre for Breast Cancer Research and Professor of Biochemical Endocrinology at The Institute of Cancer Research (ICR), and Professor Jack Cuzick and Dr Ivana Sestak from Queen Mary University of London developed CTS5 after reviewing data from two previously published studies. Together these provided information on 11,446 postmenopausal women with ER positive breast cancer who had received five years of hormone therapy (tamoxifen, anastrozole, or letrozole).
Using the data set from one previously published study, they measured how many women developed metastasis five to 10 years after they finished endocrine therapy. This was then combined with information about the tumour, which had been measured at the point of diagnosis, to produce a risk equation - CTS5.
To investigate the validity of the tool, researchers then tested CTS5 against data from the second study. CTS5 was shown to be able to accurately separate women into groups of low, intermediate, or high risk of developing a late distant recurrence breast cancer after five years of hormone therapy. The test identified 42 per cent of women as who were sufficiently low risk so that extending hormone therapy would have been of very little value.
Co-lead researcher Professor Mitch Dowsett, Head of The Royal Marsden Ralph Lauren Centre for Breast Cancer Research and Professor of Biochemical Endocrinology at The Institute of Cancer Research, London, said: "What we have developed could improve clinical practice, benefiting breast cancer patients by avoiding potentially unnecessary extended treatment. Clinicians require expertise and the best tools to help them make crucial decision on treatment for patients, decisions that can make a difference to patient's quality of life."
Queen Mary University of London researchers led on the development of the web-based CTS5 calculator, which has been designed with clinicians in mind. After inputting patient details, including age, tumour size and tumour grade, it gives an estimated 5-10 year risk of the cancer returning in another part of the woman's body, with an estimated benefit from extending their hormone therapy.
Co-lead researcher Professor Jack Cuzick from Queen Mary University of London said: "Hormone sensitive breast cancer is one of the few cancers where late recurrence is common, and predicting who is at high risk is particularly important so that they can continue hormone treatment. While our ability to predict this type of cancer is highly likely to improve in the future, we're providing a simple tool which is available now, and is easily used and well tested."
Dr Ivana Sestak from Queen Mary University of London said: "Over 50 per cent of women who have finished hormonal treatment for their breast cancer are at increased risk of developing a late metastasis. But there are no web-based calculators for predicting which women are at highest risk.
"Our tool provides a very simple way of obtaining the risk of a late metastasis for each woman individually. It is very important to identify these women in the clinic and the calculator provides help in the decision-making process."
Professor Dowsett adds: "This tool uses information that is already gathered in all patients, so could be easily used across the UK and globally at other centres."
The authors note that the data used was from previously published studies that began over 20 years ago on patients with hormone receptor positive tumours (make up about 85% of breast cancer). The only major change to the management of this specific patient population since then has been the introduction of trastuzumab for some patients, and so clinicians who are treating this specific group should be cautious of using CTS5.
This study was supported by NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, Cancer Research UK and the Susan G. Komen Foundation.
Notes to editors
The online web tool will be available for use by clinicians from Friday 24th August UK time. A password protected preview is available here: http://www.
For further information and interviews please contact Hannah.email@example.com / 0207 7811 8244. A patient case study is available for interview.
Data was taken from large scale seminal studies- ATAC (Arimidex, Tamoxifen, Alone or in Combination) and BIG 1-98.
'Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients with Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5' by Dowsett et all was published in Journal of Clinical Oncology. It is available here: http://ascopubs.
About The Royal Marsden NHS Foundation Trust
The Royal Marsden opened its doors in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education.
Today, together with its academic partner, The Institute of Cancer Research, London, it is the largest comprehensive cancer centre in Europe. It is a centre of excellence with an international reputation for ground-breaking research and pioneering the very latest in cancer treatments and technologies.
The Royal Marsden, with the Institute of Cancer Research (ICR), is the only National Institute for Health Research Biomedical Research Centre for Cancer. This supports pioneering research work carried out over a number of different cancer themes.
Since 2003, The Royal Marsden Cancer Charity has funded the latest developments in cancer research, diagnosis, treatment and patient care. Over recent years, supporters of The Royal Marsden Cancer Charity have funded facilities including the Oak Centre for Children and Young People, the da Vinci robots, the CyberKnife radiotherapy machine and the Reuben Foundation Imaging Centre.
HRH The Duke of Cambridge became President of The Royal Marsden in 2007, following a long royal connection with the hospital.
The Ralph Lauren Centre for Breast Cancer Research is a world-class facility, working with the latest technology to set a benchmark for cancer research around the world. The centre is funded by supporters of The Royal Marsden Cancer Charity, including a generous donation from Ralph Lauren.
About Queen Mary University of London
Queen Mary University of London is a world-leading research-intensive university with over 25,000 students representing more than 160 nationalities.
A member of the prestigious Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research.
In the most recent exercise that rated research in the UK, we were ranked 5th in the country for the proportion of research outputs that were world-leading or internationally excellent. We offer more than 240 degree programmes and our reputation for excellent teaching was rewarded with a silver in the 2017 Teaching Excellence Framework (TEF) awards.
Queen Mary's history dates back to 1785, with the foundation of the London Hospital Medical College. Our history also encompasses the establishment of the People's Palace in 1887, which brought accessible education, culture and recreation to the East End of London. We also have roots in Westfield College, one of the first colleges to provide higher education to women.
About The National Institute for Health Research (NIHR)
The National Institute for Health Research (NIHR): improving the health and wealth of the nation through research. Established by the Department of Health and Social Care, the
- funds high quality research to improve health
- trains and supports health researchers
- provides world-class research facilities
- works with the life sciences industry and charities to benefit all
- involves patients and the public at every step
For further information, visit the NIHR website http://www.